Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

1. Is the biology right?

• Somatic driver evidence: no · None of FLT3, KIT, PDGFRB, NR3C1 has somatic-mutation evidence in leukemia

  Rule: Open Targets has somatic-mutation evidence for the target in this cancer. Source: Open Targets: FLT3 in leukemia, 2026-11-11
• Human genetic evidence: no · No germline or somatic evidence for FLT3, KIT, PDGFRB, NR3C1 in leukemia

  Rule: Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence. Source: Open Targets: FLT3 in leukemia, 2026-11-11
• Pediatric target: yes · FLT3, KIT, PDGFRB on the FDA list

  Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study. Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
• Haematologic cancer: yes · Haematologic

  Rule: From the indication, or the registry conditions when no indication matches. Source: ClinicalTrials.gov NCT00651261, 2026-11-11

  Published context: Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid (BIO / Informa / QLS 2021, 2011–2020). Population-level, not a prediction.

• Background therapy: cytarabine, daunorubicin: standard agents, not counted in these flags.
• FLT3 (via midostaurin): Evidence types in leukemia: literature, clinical; literature listed separately from human genetics. Datasources: europepmc, clinical_precedence. · Open Targets: FLT3 in leukemia
• KIT (via midostaurin): Evidence types in leukemia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc. · Open Targets: KIT in leukemia
• PDGFRB (via midostaurin): Evidence types in leukemia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc. · Open Targets: PDGFRB in leukemia
• NR3C1 (via dexamethasone acetate): Evidence types in leukemia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc. · Open Targets: NR3C1 in leukemia

• Not loaded on this app yet: Normal-tissue expression in vital organs. Source: Human Protein Atlas (ticket 36).
• Not loaded on this app yet: Pan-essential in cell lines. Source: DepMap (ticket 36).
• Not loaded on this app yet: Approved drug on this target. Source: Drugs@FDA (ticket 30).

2. Can the result be trusted?

• Randomised: yes · Randomised allocation

  Rule: Registry allocation field. Source: ClinicalTrials.gov NCT00651261, 2026-11-11
• Small denominator: no · 717 enrolled; each patient moves a rate by 100 ÷ 717 = 0.1 points

  Rule: Enrolment under 30; the arithmetic is shown, not a benchmark. Source: ClinicalTrials.gov NCT00651261, 2026-11-11
• Primary endpoint is overall survival: yes · Overall Survival (OS)

  Rule: A registered primary outcome measure names overall survival. Source: ClinicalTrials.gov NCT00651261, 2026-11-11
• Results overdue: no · Results posted 2017-02-06

  Rule: Primary completion (actual) more than 12 months ago and no results posted to the registry. Source: ClinicalTrials.gov NCT00651261, 2026-11-11

• Not loaded on this app yet: Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff. Source: Readout extraction (ticket 32).
• Not loaded on this app yet: Primary endpoint changed between registry versions. Source: Registry versions in the store (ticket 32).

3. What must it beat?

• Not loaded on this app yet: Control-arm result and approved therapies for the same segment, with label links. Source: Drugs@FDA, FDA labels and readouts (tickets 30, 32).

4. Too crowded, or too late?

• Stopped on this target: 311 terminated, withdrawn or suspended trials of drugs against FLT3; 25 of the 200 most recent give no reason. Reasons are quoted as the registry gives them on the target page. · FLT3: what already stopped

• Not loaded on this app yet: Programs on the target by phase and months behind the leader. Source: Programs and Drugs@FDA (ticket 33).

5. Can it be approved, and stay approved?

• Single-country: no · 176 sites in 2 countries; 170 in the United States (97%)

  Rule: All listed sites are in one country; the share of US sites is shown. Source: ClinicalTrials.gov NCT00651261, 2026-11-11
• EU paediatric investigation plan: yes · EMEA-000780-PIP01-09-M08 (Midostaurin, Treatment of acute myeloid leukaemia;Treatment of malignant mastocytosis;Treatment of mast cell leukaemia): PM: decision on the application for modification of an agreed PIP, 16 Aug 2024; EMEA-003031-PIP01-21 (Dexamethasone (sodium phosphate);ofloxacin, Prevention and treatment of ocular infections, inflammations and associated manifestations): W: decision granting a waiver in all age groups for all conditions or indications, 29 Oct 2021; EMEA-002375-PIP02-18 (Dexamethasone (sodium phosphate);levofloxacin, Treatment of acute otitis externa): RP: decision refers to a refusal on a proposed Paediatric Investigation Plan, 17 Jul 2019; EMEA-002423-PIP01-18 (dexamethasone, Treatment of postoperative pain and inflammation associated with ophthalmic surgery): RP: decision refers to a refusal on a proposed Paediatric Investigation Plan, 12 Jun 2019; +6 more

  Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
• EU orphan designation: yes · EU/3/16/1774 withdrawn 18 Nov 2016: Treatment in haematopoietic stem cell transplantation; EU/3/10/765 positive 4 Aug 2010: Treatment of mastocytosis; EU/3/04/214 positive 29 Jul 2004: Treatment of acute myeloid leukaemia; EU/3/10/745 withdrawn 9 Jun 2010: Treatment of multiple myeloma; +2 more

  Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
• Authorised in the EU: yes · Neofordex: authorised since 16 Mar 2016; Ozurdex: authorised since 26 Jul 2010; Rydapt: authorised since 18 Sept 2017, orphan medicine; Dexamethasone Taw: application withdrawn; +1 more

  Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
• FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link

  Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
• FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of midostaurin, dexamethasone acetate

  Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
• Registered studies open to children: yes · 740 interventional studies of midostaurin, dexamethasone acetate include patients under 18; 158 are recruiting, not yet recruiting or active

  Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11

• Caveat: Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality.
• Rare pediatric disease voucher: FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. · FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

• Not loaded on this app yet: Precedent approvals for target, modality and endpoint; accelerated-approval status. Source: Drugs@FDA and FDA accelerated-approval tables (ticket 30).

6. Can the sponsor finish?

• Sponsor: Alliance for Clinical Trials in Oncology (academic or other) · ClinicalTrials.gov NCT00651261
• study chair: Richard M. Stone, MD, Dana-Farber Cancer Institute · Person page

• Not loaded on this app yet: Filed cash, quarterly spend and the runway arithmetic. Source: SEC XBRL company facts (ticket 37).
• Not loaded on this app yet: Sponsor's completed vs stopped oncology trials and results-reporting record. Source: Registry, by company (ticket 37).

What public data cannot tell you

Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.